Pharmacokinetics of Glucarpidase in Subjects With Normal and Impaired Renal Function

¹ Protherics Medicines Development Ltd
² New Orleans Centre for Clinical Research
³ Procter & Gamble Pharmaceuticals
⁴ Protherics Inc

^* To whom correspondence should be addressed. E-mail: marc.phillips{at}protherics.com.

	Abstract

Glucarpidase (formerly known as carboxypeptidase G2 or CPG2) is being evaluated for the adjunctive treatment of patients experiencing, or at risk of, methotrexate toxicity attributable to its delayed elimination. Delayed elimination of methotrexate can occur in patients with methotrexate-induced renal toxicity. In this study, glucarpidase pharmacokinetics were assessed in volunteer subjects with normal (n = 8) and severely impaired (n = 4) renal function. Each subject received a single intravenous dose of glucarpidase 50 U/kg (equivalent to 114.5 µg/kg) infused over 5 minutes. The mean maximum serum concentration (C_max) for glucarpidase in renally impaired subjects was 2.9 µg/mL, the mean half-life (t_1/2) was 10.0 hours, and the mean area under the serum concentration–time curve from time zero to infinity (AUC_0-) was 24.5 µgxh/mL. Similar values were found in subjects with normal renal function (mean C_max 3.1 µg/mL, mean t_1/2 9.0 hours, and mean AUC_0- 23.4µgxh/mL). The results indicated little effect of renal impairment on the serum pharmacokinetics of glucarpidase.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?